Home Newsfeeds Needham Maintains Buy on Paramount Global, Raises Price Target to $28

Needham Maintains Buy on Paramount Global, Raises Price Target to $28

Needham analyst Laura Martin maintains Paramount Global (NASDAQ:PARA) with a Buy and raises the price target from $23 to $28.

byBenzinga Newsdesk

February 17, 2023

1 minute read

Needham analyst Laura Martin maintains Paramount Global (NASDAQ:PARA) with a Buy and raises the price target from $23 to $28.

US Stocks Set For Lackluster Start Following November’s Buoyancy; Fed Chair Powell’s Speeches Take The Spotlight

By Shanthi Rexaline

December 1, 8:25 AM

U.S. stocks are priming for a cautious start in the first trading session of December following Thursday’s mixed close.

CRM

Abbott Laboratories Clocks Strong Q2 Growth In Underlying Base Business, Reaffirms FY23 Outlook

By Vandana Singh

July 20, 9:15 AM

Abbott Laboratories (NYSE: ABT) has reported Q2 FY23 adjusted EPS of $1.08, down 25% Y/Y, beating the consensus of $1.05.

ABT

News

Why GM Stock Hit A New 52-Week Low Today

By Henry Khederian

October 24, 2:45 PM

General Motors Co (NYSE: GM) shares are trading lower by 1.6% to $28.74 Tuesday afternoon, marking a new 52-week low.

Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter For Its Pediatric Selective Cytopheretic Device

By Benzinga Newsdesk

October 31, 8:10 AM

Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced its strategic partner, SeaStar Medical Holding Corporation (NASDAQ:ICU) (SeaStar

ICU

Needham Maintains Buy on Paramount Global, Raises Price Target to $28

Related Posts

US Stocks Set For Lackluster Start Following November’s Buoyancy; Fed Chair Powell’s Speeches Take The Spotlight

Abbott Laboratories Clocks Strong Q2 Growth In Underlying Base Business, Reaffirms FY23 Outlook

Why GM Stock Hit A New 52-Week Low Today

Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter For Its Pediatric Selective Cytopheretic Device